Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesalazine - Tillotts Pharma

Drug Profile

Mesalazine - Tillotts Pharma

Alternative Names: Asacol; Asacolon; Fivasa; Lixacol; Octasa; TP 05; YALDIGO; Z-206

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tillotts Pharma
  • Developer Kyowa Hakko Kirin; Kyowa Kirin; Lek Pharmaceuticals d.d.; Tillotts Pharma; Zeria
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Proctitis; Ulcerative colitis
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2019 Tillotts Pharma and Menarini Group sign an agreement for the marketing and distribution of Mesalazine in China
  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
  • 22 Jan 2019 Launched for Ulcerative colitis in Norway, Netherlands, Iceland and Denmark (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top